Bank of New York Mellon
ATOS icon

Bank of New York Mellon’s Atossa Therapeutics ATOS Stock Holding History

Bank of New York Mellon’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-743
Closed -$6.58K – 4200
2025
Q4 		$6.58K Hold
743
– – ﹤0.01% 4179
2025
Q3 		$9.66K Hold
743
– – ﹤0.01% 4168
2025
Q2 		$9.25K Sell
743
-18,572
-96% -$222K ﹤0.01% 4129
2025
Q1 		$195K Hold
19,315
– – ﹤0.01% 3892
2024
Q4 		$274K Sell
19,315
-928
-5% -$18.1K ﹤0.01% 3828
2024
Q3 		$462K Sell
20,243
-7,201
-26% -$145K ﹤0.01% 3564
2024
Q2 		$490K Buy
27,444
+26,602
+3,159% +$589K ﹤0.01% 3594
2024
Q1 		$22.7K Sell
842
-2,639
-76% -$42.4K ﹤0.01% 4111
2023
Q4 		$46K Sell
3,481
-3,909
-53% -$42.2K ﹤0.01% 4163
2023
Q3 		$81.6K Sell
7,390
-120
-2% -$1.74K ﹤0.01% 4111
2023
Q2 		$142K Sell
7,510
-2,575
-26% -$31.2K ﹤0.01% 4042
2023
Q1 		$110K Hold
10,085
– – ﹤0.01% 4058
2022
Q4 		$80K Sell
10,085
-52
-0.5% -$597 ﹤0.01% 4162
2022
Q3 		$127K Hold
10,137
– – ﹤0.01% 4152
2022
Q2 		$166K Sell
10,137
-23,899
-70% -$377K ﹤0.01% 4119
2022
Q1 		$639K Sell
34,036
-608
-2% -$12.4K ﹤0.01% 3568
2021
Q4 		$832K Buy
34,644
+2,825
+9% +$103K ﹤0.01% 3489
2021
Q3 		$1.56M Buy
31,819
+781
+3% +$45.4K ﹤0.01% 3143
2021
Q2 		$2.94M Buy
31,038
+28,643
+1,196% +$1.52M ﹤0.01% 2762
2021
Q1 		$76K Buy
+2,395
New +$87.5K ﹤0.01% 4198
2018
Q2 		– Sell
-104
Closed -$8K – 4210
2018
Q1 		$8K Buy
+104
New +$9.69K ﹤0.01% 4294

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon's ATOS Position: Q1 2026 in Review

Bank of New York Mellon sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 743 shares — an estimated $6.58K sold.

Bank of New York Mellon first reported a position in ATOS in Q1 2018 and held it in 21 quarters. The position peaked at $2.94M in Q2 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Bank of New York Mellon reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of New York Mellon sold 743 Atossa Therapeutics shares in Q1 2026, an estimated $6.58K.
  • Bank of New York Mellon first reported a position in Atossa Therapeutics in Q1 2018 and held it in 21 quarters.
  • Bank of New York Mellon's Atossa Therapeutics position peaked at $2.94M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Bank of New York Mellon's 13F filing for Q1 2026, filed 5 May 2026.